Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Lauper

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
RMD Open|November 30, 2018
Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registriesKim Lauper, Denis Mongin, Florenzo Iannone, et al.
JAMA Neurology|February 25, 2022
Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With OcrelizumabNatacha Madelon, Nelli Heikkilä, Irène Sabater Royo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2021
Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort StudyNatacha Madelon, Kim Lauper, Gautier Breville, et al.
RMD Open|June 23, 2026
Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management RegistryAnnik Steimer, Andrea Götschi, Jonas Brändli, et al.
Frontiers in Immunology|October 31, 2022
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseasesCatherine E Raptis, Christoph T Berger, Adrian Ciurea, et al.
RMD Open|June 12, 2024
Evaluating the participation of junior members and patient and healthcare professionals representatives in EULAR task forces: results from an international surveyPierre-Antoine Juge, Tue Wenzel Kragstrup, Luis Fernando Perez-Garcia, et al.
Annals of the Rheumatic Diseases|May 7, 2018
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaborationKim Lauper, Dan C Nordström, Karel Pavelka, et al.
Seminars in Arthritis and Rheumatism|July 9, 2019
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritisKim Lauper, Denis Mongin, Florenzo Iannone, et al.
Rheumatology (Oxford, England)|May 14, 2021
Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR databaseMichele Iudici, Matthias Jarlborg, Kim Lauper, et al.
Rheumatology (Oxford, England)|December 13, 2023
A potential role for chlamydial infection in rheumatoid arthritis developmentCeline Lamacchia, Romain Aymon, Brian C Hattel, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
RMD Open|November 30, 2018
Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registriesKim Lauper, Denis Mongin, Florenzo Iannone, et al.
JAMA Neurology|February 25, 2022
Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With OcrelizumabNatacha Madelon, Nelli Heikkilä, Irène Sabater Royo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2021
Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort StudyNatacha Madelon, Kim Lauper, Gautier Breville, et al.
RMD Open|June 23, 2026
Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management RegistryAnnik Steimer, Andrea Götschi, Jonas Brändli, et al.
Frontiers in Immunology|October 31, 2022
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseasesCatherine E Raptis, Christoph T Berger, Adrian Ciurea, et al.
RMD Open|June 12, 2024
Evaluating the participation of junior members and patient and healthcare professionals representatives in EULAR task forces: results from an international surveyPierre-Antoine Juge, Tue Wenzel Kragstrup, Luis Fernando Perez-Garcia, et al.
Annals of the Rheumatic Diseases|May 7, 2018
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaborationKim Lauper, Dan C Nordström, Karel Pavelka, et al.
Seminars in Arthritis and Rheumatism|July 9, 2019
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritisKim Lauper, Denis Mongin, Florenzo Iannone, et al.
Rheumatology (Oxford, England)|May 14, 2021
Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR databaseMichele Iudici, Matthias Jarlborg, Kim Lauper, et al.
Rheumatology (Oxford, England)|December 13, 2023
A potential role for chlamydial infection in rheumatoid arthritis developmentCeline Lamacchia, Romain Aymon, Brian C Hattel, et al.
Pageof 7